appointmentF-star, a biopharmaceutical company developing novel immuno-oncology bispecific antibodies, has announced the opening of its new facility in the Eddeva building on the Babraham Research Campus in Cambridge, UK. The company also announced the appointment of Michael Davies as VP Protein Sciences.

The new facility will house F-star’s expanded team, which has grown to just over 60 members of staff during the last year. F-star has successfully hired several key employees and developed its capabilities to maximize the potential of its powerful modular antibody technology for the discovery of bispecific antibody therapeutics and further progress its portfolio of novel immuno-oncology compounds into the clinic.

Mike Davies joins F-star as VP Protein Sciences from CPI Biologics where he worked as Head of Analytical Strategy, Biologics. He has more than 15 years of experience in the development, manufacture and commercialization of recombinant protein therapeutics. He has successfully run Chemistry, Manufacturing and Control (CMC) projects to support the launch of several commercial products. Previously, he worked at Lonza where he held leadership roles in analytical strategy and development.

In January, F-star announced a collaborative discovery and development agreement with AbbVie for the development of bispecific antibodies against two immuno-oncology targets. This collaboration further leverages the strength of F-star’s technology and follows ongoing partnerships with leading biopharmaceutical companies including Bristol-Myers Squibb, Merck Serono and Boehringer Ingelheim.

John Haurum, Chief Executive Officer of F-star, said: “At F-star, we are proud to be developing the next generation of cancer therapies through our leadership in bispecific antibodies. The new facility will create an ideal environment for our staff to harness the power of our bispecific platform. We are pleased to welcome Mike to the team and look forward to working with him. His strong experience in the development and commercialisation of recombinant protein therapeutics will further enable us to progress our immuno-oncology pipeline into the clinic.”